Vestibular Migraine Clinical Trials
Here are the 3 most popular medical studies for vestibular migraine
Behavioural Intervention
Visual Feedback Goggles for Positional Vertigo
This trial is a prospective, single-center, interventional study of the VertiGONE goggle in the treatment of BPPV. The study will enroll 100 subjects who will be randomized to either the VertiGONE goggle group or the control group. The primary outcome measure will be the resolution of vertigo, as measured by the Dizziness Handicap Inventory (DHI).
Device
Otoband Experimental +1 More for Vestibular Migraine
This trial aims to compare two devices for treating chronic Vestibular Migraines in adults. Participants will be enrolled for up to 50 days and will use one of the study devices as instructed.
Popular filter options for vestibular migraine trials
Vestibular Migraine Clinical Trials With No Placebo
View 12 vestibular migraine medical studies that do not have a placebo group.
Behavioural Intervention
Hearing aids equipped with motion sensing abilities for Vertigo
This trial aims to create and test hearing aids with sensors and AI to help assess and reduce the risk of falls, improve speech clarity, track activity levels, and social interactions. The goal is to use
Frequently Asked Questions
Introduction to vestibular migraine
What are the top hospitals conducting vestibular migraine research?
When it comes to cutting-edge clinical trials focused on vestibular migraine, several hospitals are making significant strides in research and treatment. Otolith Labs, located in Washington, leads the way with two active trials dedicated to this debilitating condition. Although relatively new to the field, having recorded their first trial in 2021, their commitment to finding innovative solutions is evident. Moving down south to Pasadena, California, Kaiser Permanente Southern California joins the ranks with one ongoing vestibular migraine trial and a promising track record of being at the forefront of medical advancements; they initiated their first study in 2022. In Amqui, Canada, Centre Hospitalier d'Amqui has also made substantial contributions through its active vestibular migraine trial and marks a milestone as it delves into this specific area for the first time this year.
Similarly joining forces are Centre Hospitalier de Matane and Centre Hospitalier de Montmagny—both situated in different regions of Canada—embracing groundbreaking research by conducting active investigations into vestibular migraines as well. These hospitals each have one ongoing clinical trial under their belts while demonstrating an unwavering dedication that commenced just recently in 2022.
The pursuit of understanding and combating vestibular migraines requires collaboration from diverse institutions across countries. The efforts put forth by these leading hospitals not only elevate our knowledge about this complex condition but also pave the way for much-needed breakthroughs that will improve the lives of those affected worldwide
Which are the best cities for vestibular migraine clinical trials?
In the realm of vestibular migraine clinical trials, a few cities have emerged as key players in advancing research and treatment. Washington, D.C., boasts 4 active trials investigating Ebselen, the efficacy of Otoband versus Sham A, and other interventions. Likewise, Los Angeles, California has 4 ongoing studies exploring Montelukast and Ebselen among other potential therapies. San Francisco showcases 3 active trials focusing on Galcanezumab Prefilled Syringe, Ebselen, and more. Lastly, San Diego and New york each house 2 active trials centered on evaluating the effectiveness of Ebselen along with other experimental treatments. These cities offer valuable opportunities for individuals affected by vestibular migraines to participate in cutting-edge clinical trials that may pave the way for improved management and relief of symptoms.
Which are the top treatments for vestibular migraine being explored in clinical trials?
In the realm of vestibular migraine treatment, two emerging options are capturing attention in clinical trials. The Frenzel Lens, introduced just recently in 2022, is currently being explored in one active trial dedicated to vestibular migraines. Montelukast is another contender gaining traction with its inclusion in one ongoing clinical trial since its listing last year in 2021. As researchers delve deeper into these potential treatments, they offer hope for those living with the challenges of vestibular migraines and pave the way for better management strategies moving forward.
What are the most recent clinical trials for vestibular migraine?
Exciting advancements are underway in the field of vestibular migraine research, offering renewed hope for those affected by this debilitating condition. One notable clinical trial focuses on the efficacy of Ebselen—a promising drug candidate—in treating vestibular migraines. Another study explores the potential benefits of Montelukast, while a separate trial investigates Lamotrigine and Bupropion as potential treatment options. Moreover, Galcanezumab Prefilled Syringe is being evaluated for its effectiveness in managing symptoms associated with vestibular migraines. These trials signify significant progress towards improving the lives of individuals grappling with this challenging disorder.
What vestibular migraine clinical trials were recently completed?
In recent times, several clinical trials investigating vestibular migraine have reached completion, shedding light on potential advancements in its treatment. Notably, a trial examining the effectiveness of Uproleselan was concluded by Washington University School of Medicine in October 2021. Furthermore, the National Cancer Institute successfully completed a trial involving mRNA-1273 for this condition in September 2021. Lastly, AgenTus Therapeutics wrapped up their agenT-797 study related to vestibular migraine in January 2021. These significant milestones signify progress and offer hope for individuals grappling with vestibular migraine as researchers continue to strive towards improved treatments.